Pulmonary hypertension classification

Revision as of 01:19, 15 May 2014 by GeraldChi (talk | contribs)
Jump to navigation Jump to search

Pulmonary Hypertension Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pulmonary hypertension from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pulmonary hypertension classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Pulmonary hypertension classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pulmonary hypertension classification

CDC on Pulmonary hypertension classification

Pulmonary hypertension classification in the news

Blogs on Pulmonary hypertension classification

Directions to Hospitals Treating Pulmonary hypertension

Risk calculators and risk factors for Pulmonary hypertension classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Richard Channick, M.D.; Assistant Editor(s)-in-Chief: Ralph Matar, Lisa Prior, Ann Slater, R.N.

Overview

Pulmonary hypertension has been previously divided into two categories: primary (currently known as idiopathic pulmonary arterial hypertension [IPAH]) and secondary. However; given the fact that some subcategories of secondary pulmonary hypertension share several similarities with primary pulmonary hypertension in terms of pathology, progression and response to therapy, the WHO (World Health Organization) has based its reclassification of pulmonary hypertension on the mechanism of the disease.

Classification

WHO Classification of Pulmonary Hypertension[1]

During the World Symposium on Pulmonary Hypertension (WSPH), five groups of disorders that cause pulmonary hypertension were identified: pulmonary arterial hypertension (Group 1); pulmonary hypertension due to left heart disease (Group 2); pulmonary hypertension due to chronic lung disease and/or hypoxia (Group 3); chronic thromboembolic pulmonary hypertension (Group 4); and pulmonary hypertension due to unclear multifactorial mechanisms (Group 5). This classification has been adopted by the Guidelines Committee of the European Society of Cardiology (ESC), European Respiratory Society (ERS), and International Society of Heart and Lung Transplantation (ISHLT), and is currently used by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the labelling of new drugs approved for pulmonary hypertension.

  • 3. Pulmonary hypertension due to lung diseases and/or hypoxia
  • 4. Chronic thromboembolic pulmonary hypertension (CTEPH)
Abbreviations: BMPR, bone morphogenic protein receptor type II; CAV1, caveolin-1; ENG, endoglin; HIV, human immunodeficiency virus.

Other Classification

The Venice 2003 Revised Classification System

In 2003, the 3rd World Symposium on Pulmonary Arterial Hypertension was convened in Venice to modify the classification based on the new understanding of disease mechanisms. The revised system developed by this group provides the current framework for understanding pulmonary hypertension.

The system includes several improvements over the former 1998 Evian Classification system. Risk factor descriptions were updated, and the classification of congenital systemic-to pulmonary shunts was revised. A new classification of genetic factors in PH was recommended, but not implemented because available data were judged to be inadequate.

The Venice 2003 Revised Classification system can be summarized as follows:[2]

  • WHO Group I - Pulmonary arterial hypertension (PAH)
  • WHO Group II - Pulmonary hypertension associated with left heart disease
  • WHO Group III - Pulmonary hypertension associated with lung diseases and/or hypoxemia
  • WHO Group IV - Pulmonary hypertension due to chronic thrombotic and/or embolic disease
  • WHO Group V - Miscellaneous

Venice Clinical Classification of Pulmonary Hypertension (2003)

Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels (adenopathy, tumor, fibrosing mediastinitis

References

  1. Simonneau, G.; Gatzoulis, MA.; Adatia, I.; Celermajer, D.; Denton, C.; Ghofrani, A.; Gomez Sanchez, MA.; Krishna Kumar, R.; Landzberg, M. (2013). "Updated clinical classification of pulmonary hypertension". J Am Coll Cardiol. 62 (25 Suppl): D34–41. doi:10.1016/j.jacc.2013.10.029. PMID 24355639. Unknown parameter |month= ignored (help)
  2. Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23-25, 2003. J Am Coll Cardiol 2004 Jun 16;43(12 Suppl S):1S-90S. PMID 15194171.

Template:WikiDoc Sources